The FTC is pausing its challenge of Amgen’s proposed $28 billion buyout of Horizon Therapeutics for several weeks to explore alternative ways of resolving the case, including a possible settlement.
The move, disclosed in a filing on the FTC’s website, marks the latest twist in a…
Click here to view original post
